Zanidatamab mediated concentration-dependent reduction in cell viability in high HER2 expressing breast (BT-474, SK-BR-3, ZR-75-30, HCC2218, AU565, HCC1419), gastric (NCI-N87), esophageal (OE-19), and lung (NCI-H2170), and in the HER2-low MDA-MB-175-VII cancer cell lines (Fig. 6a, Supplementary Table 6). The gene discussed is ERBB2; the disease is cancer.